human cxcl10 ip 10 immunoassay  (ALPCO)

Journal: Cancers

Article Title: Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHRII) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogrammation and T Cell Activation

doi: 10.3390/cancers13081845

Figure Lengend Snippet: Variation of pharmacodynamic markers measured in blood samples and biopsies of patients from C201 and C101 studies. ( A ) Detection of CD69 as a marker of activation of monocytes, regulatory and CD8 + T cells in blood samples of patients ( n = 20) with colorectal cancer treated with murlentamab (single agent and in combination with trifluridine/tripiracil). Data shown (boxplots) are the results from 20 patients. * p < 0.05; ** p < 0.01. p values were determined using one-way ANOVA analysis followed by Tukey’s multiple comparisons test. ( B ) Detection of ICOS (inducible co-stimulatory molecule) as a marker of lymphocyte activation in blood samples of patients with ovarian cancer treated at Gustave Roussy (Paris, France) with murlentamab in combination with carboplatin + paclitaxel ( n = 4). ( C ) Detection of CXCL9 ( n = 16) and CXCL10 ( n = 15) release in blood samples of all patients treated with murlentamab single agent in C201. ( D ) Detection of co-staining CD14/CD163 ( n = 8) and of ICOS ( n = 4) as markers of immune system regulation in FFPE (Formalin-Fixed Paraffin-Embedded) biopsies obtained from the C201 study. ( E ) Image and quantification of CD16 ( n = 5), co-staining CD16/granzyme B (GrZB) ( n = 4), and CD8 ( n = 4) as markers of immune system activation in FFPE biopsies obtained from the C201 study. ( F ) Image and quantification of CD16/granzyme B (GrZB) co-staining in FFPE biopsies obtained from the C101 study ( n = 2).

Article Snippet: CXCL9 and CXCL10 quantification was performed using, respectively, Quantikine ® ELISA Human CXCL9/MIG Immunoassay and Quantikine ® ELISA Human CXCL10/IP-10 Immunoassay kits (R & D System, Abingdon, UK) according to manufacturer’s protocols.

Techniques: Marker, Activation Assay, Staining, Formalin-fixed Paraffin-Embedded

Journal: Cancers

Article Title: Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHRII) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogrammation and T Cell Activation

doi: 10.3390/cancers13081845

Figure Lengend Snippet: Murlentamab opsonization of SKOV3-R2 + orients naïve macrophages and reprograms TAMs towards an M1-like profile. SKOV3-R2 + ovarian tumor cells were labeled with different 3C23K antibodies (3C23K-FcKO control, 3C23K-CHO normally fucosylated or murlentamab the low fucosylated form) and cultured in the presence of human monocyte-derived macrophages from healthy donors unstimulated (M0) or stimulated with M-CSF and IL-10 (TAMs). ( A ) The proportion of macrophages expressing M1/M2 membrane markers (CD32, CD64, CD80, TLR2, CD163, CD36 and CD206) was determined by flow cytometry after three days of co-culture with SKOV3-R2 + cells. ( B ) The release of cytokines (IL1β, IL12, TNFα, IL6, IFNγ, IL10) and chemokines (CCL2, CCL4, CCL5, CXCL9 and CXCL10) in the culture medium was determined by AlphaLISA after three days of co-culture with SKOV3-R2 + cells. Data shown (boxplots) are the results from three different experiments (performed with three different healthy donors). * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. p values were determined using one-way ANOVA analysis followed by Tukey’s multiple comparisons test.

Article Snippet: CXCL9 and CXCL10 quantification was performed using, respectively, Quantikine ® ELISA Human CXCL9/MIG Immunoassay and Quantikine ® ELISA Human CXCL10/IP-10 Immunoassay kits (R & D System, Abingdon, UK) according to manufacturer’s protocols.

Techniques: Labeling, Control, Cell Culture, Derivative Assay, Expressing, Membrane, Flow Cytometry, Co-Culture Assay